Trial Profile
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of CEP-33457 in Patients With Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2022
Price :
$35
*
At a glance
- Drugs Forigerimod (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms Celestial 47
- Sponsors Cephalon
- 20 Nov 2012 Results have been presented at the 2012 American College of Rheumatology Meeting (ACR-2012) according to an ImmuPharma media release.
- 14 Nov 2012 Primary endpoint 'Systemic-Lupus-Erythematosus-Responder-Index' has not been met.
- 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.